Hyperbaric oxygen for neurologic indications. Action plan for multicenter trials in: stroke, traumatic brain injury, radiation encephalopathy and status migrainosus  by Whelan, Harry T. & Helms, Ann K.
Original research article/Artykuł oryginalny
Leading article/Artykuł redakcyjny
Hyperbaric oxygen for neurologic indications. Action plan for
multicenter trials in: stroke, traumatic brain injury, radiation
encephalopathy and status migrainosus
Tlenoterapia hiperbaryczna we wskazaniach neurologicznych. Plan badania
wieloośrodkowego w przypadkach udaru, pourazowego uszkodzenia mózgu,
encefalopatii popromiennej i stanu migrenowego
Harry T. Whelan *, Ann K. Helms
Department of Pediatric Neurology, Medical College of Wisconsin, United States
p e d i a t r i a p o l s k a 8 7 ( 2 0 1 2 ) 4 2 9 – 4 3 7
a r t i c l e i n f o
Article history:
Received: 21.06.2012
Accepted: 22.07.2012
Published on line: 03.08.2012
Keywords:
 Hyperbaric oxygen
 Stroke
 Traumatic brain injury
 Radiation encephalopathy
 Migraine
Słowa kluczowe:
 tlenoterapia hiperbaryczna
 udar
 pourazowe uszkodzenie mózgu
 encefalopatia popromienna
 migrena
a b s t r a c t
Introduction: There is great interest in using hyperbaric oxygen (HBO) to treat neurological
disease. The exquisite sensitivity of neural tissue to hypoxia makes increased oxygenation
attractive as a therapy for disease processes that induce ischemia, edema, and, more
recently, apoptosis. Four things speciﬁcally exist as targets for future projects and clinical
trials: (1) stroke (2) traumatic brain injury (3) radiation induced necrosis and (4) status
migrainosus.Methods: Speciﬁc aims: Stroke: determine if the use of HBO in the treatment of
acute ischemic stroke is effective at improving outcomes. TBI: determine whether use of
HBO in the acute state after traumatic brain injury is effective at improving outcomes and
reducing elevated ICP. RIN: determine whether HBO treatment of radiation necrosis of brain
results in improvement of neurological function and reduction of necrosis. Migraine:
determine whether use of HBO will relieve headache pain in status migrainosus. Results:
Stroke: there is evidence from animal studies that focal cerebral ischemiamay improve after
HBO treatment. TBI: the interest in using HBO to treat TBI is based upon the premise that
hypoxia, edema and apoptosis play signiﬁcant roles in the pathophysiology of the disease.
RIN: the evidence suggests that in caseswhere either the patient is not improving onmedical
therapies or when surgical resection is not possible, HBO should be considered as
a treatment option. Migraine: there is some evidence looking at HBO as an effective
treatment of acute migraine attack. Summary: Each is discussed further with proposed
study design and justiﬁcation for their respective parameters. As our action plan moving
forward, it is our goal to investigate in each areawithmultidisciplinary,multi-centered, case
controlled double blind crossover studies.
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Since the early days of hyperbaric medicine, there has been
interest in using HBO2T to treat neurological disease. The
exquisite sensitivity of neural tissue to hypoxia makes
increased oxygenation attractive as a therapy for disease
processes that induce ischemia, edema, and, more recently
recognized apoptosis. Four conditions were speciﬁcally targe-
ted for future projects and clinical trials: (1) stroke (2) traumatic
brain injury (3) radiation induced necrosis and (4) status
migrainosus.
Each is discussed and presented as a proposed study design
with justiﬁcation for study parameters. It is our goal to present
this publicly to stimulate further discussion and to aid in the
development of multidisciplinary, multi-centered, controlled,
blinded trials in each of these important areas of investigation.
As such, we speciﬁcally ask for reader comments on the
trials proposed.
Stroke
Speciﬁc aim
To determine if the use of HBO2T in the treatment of acute
ischemic stroke is effective at improving outcomes.
The largest body of evidence involving the use of
hyperbaric oxygen for neurologic illness is found in the ﬁeld
of cerebral ischemia, which was reviewed by Helms et al. [1].
At the center of an infarct, blood ﬂow is completely absent,
causing neurons to die within a matter of minutes. This area,
therefore,may not be amenable to treatment after the start of
symptoms. The region of the brain that draws the most
interest is the penumbra, where evidence has shown that
blood ﬂow is diminished, but not absent. The cells in this
region remain viable for a prolonged period, and can be saved
if adequate perfusion is restored [2]. The only FDA approved
therapies for acute ischemic stroke include tPA, and inter-
ventional intra-arterial treatments aimed at restoring blood
ﬂow to the ischemic penumbra [3–6], butmust be used within
theﬁrst fewhours of theonset of symptoms [7, 8]. There is also
evidence that a percentage of the cells subjected to prolonged
ischemia will inevitably undergo apoptosis, either after
prolonged ischemia or due to reperfusion injury in the case
of temporary ischemia [9–12]. As a result, there has been great
interest in using HBO2T for the added beneﬁt of its anti-
inﬂammatory and anti-apoptotic properties [13–18].
There is reasonable evidence from animal studies, invol-
ving mice, rats, gerbils, and cats that damage from focal
cerebral ischemia is ameliorated after treatment with HBO2T
(1). Several human trials investigating the use of HBO2T for
ischemic stroke have also been performed. Most of these
lacked controls, as well as uniform standards for inclusion
criteria and outcome measurement. There have been three
prominent randomized controlled studies that have evaluated
HBO2T in ischemic stroke, none of which where able to
demonstrate statistically signiﬁcant beneﬁt [19–21]. Onemight
conclude from this that HBO2T is an ineffective treatment for
ischemic stroke, however, it should be noted that these studiesenrolled patients well after the therapeutic window of 6–12 h
suggested by previous animal studies. Additionally, two of the
three also used lower doses of HBO2T thanwas found effective
in animal studies. Based on our present understanding of
ischemia, one would not expect improvement in measured
outcomes under these conditions.
It seems therefore reasonable to assess patients presenting
for potential HBO2T for a pattern of penumbra as this provides
the strongest evidence of recoverable tissue. As the ischemic
penumbra represents the area which is expected to be most
salvageable, it is reasonable to determinewhether a penumbra
is or is not present in patients undergoing experimental
treatment with HBO2T On MRI, penumbra is represented by
perfusion–diffusion mismatch [6]. More simply stated, we
must ﬁnd the area of brain which is dying in hope that HBO2T
can still save it before it is dead. This is called ischemic
penumbra. In the rat model of focal ischemic stroke produced
via thrombotic occlusion of the MCA, MRI revealed perfusion–
diffusion mismatch which persists up to 6–12 h after the
occlusion. In patients suchmismatch is usually present during
the ﬁrst 6 h after stroke [22]. Noticeably, HBO2T was effective
against experimental stroke if administeredwhen a penumbra
is typically present in the brain [23]. HBO2T administered at
a time when penumbra is usually gone (e.g. at 23 h) may even
be harmful [24]. The clinical trials done with HBO2T so far did
not follow this paradigm, which creates the most important
discrepancy between experimental and clinical work. We
propose that the evaluation of patients in any future clinical
trial should include separate subgroup analyses of patients
with and without conﬁrmed penumbra as the impact on
outcomes may be different in these two groups.
As the accepted standards of stroke care are paramount
in treatment of any patient presenting with acute stroke,
patients presenting within the therapeutic window for tPA
should be treatedwith tPA but should be considered for HBO2T
as well if they have persistent neurologic deﬁcits on physical
examination and can be treated within the time window. This
is because even in cases of temporary ischemia HBO2T has
shown beneﬁt in animal studies through decreases in
reperfusion injury [25].
Study design
Subjects presenting to the ED with a presumed diagnosis of
stroke will be evaluated by a neurologist. Inclusion requires
the determination of anterior circulation ischemia by the
clinical judgment of the examiner, meaning that the stroke is
restricted to the middle or anterior cerebral artery territory.
Both males and females at least 18 years-old with onset of
symptoms less than6 hwill beevaluatedbyacertiﬁedexaminer
using the National Institute of Health Stroke Scale (NIHSS) [26].
While this may seem a very high standard in terms of timing,
this is consistent with the recommendations of the American
Stroke Association recommending that assessment and treat-
ment of acute stroke patients commence within 60min of
presentation to the emergency department [27].
A minimum score of four on the NIHSS is needed for
inclusion. The premorbid modiﬁed Rankin scale score (mRS)
will be evaluated by discussing with the patient/family as
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scores above a mRS of 0–1, or it is unable to be assessed, the
patient will be excluded. Treatment must begin, i.e. the
chamber door must be closed, within 6 h of the onset of
symptoms. Patients who are candidates for tPA will be
included, but must complete their tPA treatment prior to
undergoing HBO2T. Asmost patients receiving tPA do so in the
ﬁrst 3 h, and the infusion lasts one hour, this does allow time
to complete the treatment and then proceed to the hyperbaric
chamber.
A non-contrast head CT at presentation will be reviewed to
assess for ICH or other intracranial pathology that would
warrant exclusion. After informed consent for inclusion of the
study is obtained an ABG will be drawn and chest X-ray
performed to assess for any underlying pulmonary disease
which could be a contraindication forHBO2T. AnMRI scanwill
be performed with diffusion weighted and perfusion weigh-
ted sequence to assess for the presence of a penumbra.
Patients without penumbra will not be excluded, as there is
evidence that there may be beneﬁt to ischemic cells after
reperfusion [25, 29], however themechanism and effect could
be quite different, and so these two groups should be
considered separately. This will be recorded and patients
will be later placed into two groups, penumbra and no
penumbra for analysis. As it would be prohibitively time
consuming to require reading the MRI for a diffusion
perfusion mismatch prior to randomization, the presence
or absence of penumbra should be analyzed later through
subgroup analysis. This would also avoid unnecessary HBO2T
treatment delays.
If no exclusion exists, patient will be randomized to
standard of care plus HBO2T or standard of care plus
a sham treatment of air at minimal pressure increase to
maintain patient blinding. HBO2Twill consist of one session of
100% oxygen at 2.4 ATA for 90 min. The selection of this dose is
based on several factors. First, the FDA has approved HBO2T at
a dose of 2.4 ATA for 90 min for numerous conditions and it is
well tolerated [30]. Second, this dose, and limitation to a single
treatment, (a single exposure) at this pressure is also more
consistent with animal studies which have shown efﬁcacy of
HBO2T in cerebral ischemia [13, 15–18, 31–38].
All patients enrolled will undergo repeat NIHSS, mRS scale,
Barthel index [39] and Glasgow outcomes scale [40] at 7 days
performed by an examiner blinded to their treatment. These
assessments will be repeated at 90 days with a follow-up
appointment to clinic, similar to the outcomes in the NINDS
(National Institute of Neurologic Diseases) trial which found
tPA to be effective [3].
Primary outcome will be the mRS, and NIHSS scores as in
the NINDS trial. Secondary outcomes will include the Barthel
index score, Glasgow outcome scale score, length of hospital
stay, rates of ICH, mortality and discharge location. Sample
size would be determined based on a 20% absolute difference
in good outcome (score 0–1 on the modiﬁed Rankin scale) at
three months. In the original tPA trial, approximately 25–28%
of the placebo group and 39–47% of the tPA group achieved this
outcome [3].
If this 6 h trial shows safety and efﬁcacy, a second tier could
be added extending to 12 h for patients with a documented
penumbra.Traumatic brain injury
Speciﬁc aims
To determine whether use of HBO2T in the acute state after
traumatic brain injury is effective at improving functional and
mortality outcomes.
To determine whether use of HBO2T in the acute state after
traumatic brain injury is effective at reducing elevated
intracranial pressure (ICP).
Traumatic brain injury (TBI) is one of the leading causes of
disability in the United States, affecting more than 1.4 million
people yearly [41]. Although the primary injury to the brain
sustained at the time of the trauma is usually not reversible, it
is the secondary injury occurring in the hours and days
following the initial injury that provides more opportunities
for treatment to preserve tissue and function. In addition to
the initial injury, a large contributor tomorbidity andmortality
is cerebral ischemia resulting from post-traumatic hypoxia
and hypotension [42]. On a microscopic level, abnormalities of
calcium and potassium homeostasis, mechanical membrane
disruption, excitotoxicity, and altered glucosemetabolismalso
contribute to cellular damage, which in turn cause edema and
neuronal cell death [43]. Cell death in the form of both necrosis
and apoptosis occurs in the areas surrounding the primary
injury, but can also occur at more distant areas [44]. Increased
intracranial pressure from edema, as well as from contusions
and hemorrhages, contributes to secondary injury by increa-
sing ischemia, and derangement of cellular metabolism, and
can lead to herniation and death [45, 46].
The interest in using HBO2T to treat TBI is based upon the
premise that hypoxia, edema and apoptosis play signiﬁcant
roles in the pathophysiology of the disease.
Only a few studies have directly compared HBO2T to
standard of care in acute TBI. Most recently Rockswold et al.
[47] published a treatment effect in acute TBI lowering
intracranial pressure for 3 days using 60 min of HBO2T at 1.5
ATA. In 1976, Artru et al. [48] randomized 60 patientswhowere
in coma after TBI for an average of 4.5 days after their injuries,
and treated them at 2.5 ATA for 60 min daily over 10 days with
a 4 day break repeated versus standard of care. At one year, the
study showed non-signiﬁcant trends towards shorter coma
andhigher rate of consciousness in theHBO2T group.Mortality
was not affected. The only signiﬁcant improvements were in
a subgroup of young patients with brainstem injury who had
higher rates of consciousness at one month, (HBO2T 67% vs
control 11%). In 1974, Holbach alternated 99 patients in coma
with acute midbrain syndrome to either standard care or
HBO2T at 1.5 ATA and saw signiﬁcant improvements in
mortality (53% vs 74%) and good outcome on the Glasgow
Outcome Scale (33% vs 6%) [49]. More recently, Rockswold et al.
randomized 168 TBI patients between 6 and 24 h after injury
with GCS of 9 or less to HBO2T at 1.5 ATA for 60 min every 8 h
for 2 weeks versus standard care [50]. At 12 months, blinded
examiners saw no change in outcome among survivors, but
there was a signiﬁcant decrease in mortality (17% vs 32%) at
one year. A smallmore recent trial randomized patients at day
3with a GCS of less than 9 to HBO2T at 2.5 ATA for 400–600 min
every four days for 3 or 4 treatments versus standard care [51].
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group achieved a good outcome at 6 months (83% vs 30%).
A recently published clinical study of a subacute TBI
population included patients who had an initial GCS score
of 3–12. Subjects were treated initially at an average of 28 days
post-insult/injury with 20 treatments lasting 90 min each of
2.0 ATA. Despite enrollment at such a late time, theywere able
to demonstrate a signiﬁcant beneﬁt from 20 lasting 90 min
each of 2.0 ATAHBO2Twhen baseline comparisonsweremade
at 6 months post-treatment in the number of patients
achieving a Glasgow Outcome Scale level of 4 (moderate
disability) subgroup of the patients was evaluated [52].
At ﬁrst glance this data might lead one to question why
HBO2T is not now standard care for TBI. The problem with the
above studies is that none were blinded, there were no sham
controls, and there was extreme variability in criteria of
inclusion, time of enrollment, and type of treatment given.
Therefore, because these studies were so poorly controlled,
it is impossible to say whether there was any overall beneﬁt in
the number of those who returned to reasonable cerebral
function.
Study design
Patients arriving to the Emergency Department with
a presumed diagnosis of diffuse axonal injury by history will
be evaluated by a neurologist or neurosurgeon. Inclusions in
the study requires the patient, either male or female, be at
least 18 years-old and have a GlasgowComa Score (GCS) of 8 or
less at time of presentation. HBO2Tmust be initiatedwithin 6 h
of the traumatic event. Past medical history including mRS,
will be gathered from family if present to assess for possible
contraindications. If this information is unavailable the
patient will be excluded. Patients with a premorbid mRS > 1
will also be excluded. Patients who require other intervention
such as surgical hematoma evacuation or medical therapy
including administration of agents to reduce ICP will not be
excluded provided that HBO2T is initiated within 6 h of the
trauma.
AnMRI with diffusionweighted imagingwill be obtained at
presentation to conﬁrm type and extent of injury, and to
assess for intracranial pathology that would warrant exclu-
sion, as well as for comparison at a later date. ABG will be
drawn and chest X-ray will be done to assess for underlying
pulmonary disease which could be a contraindication for
HBO2T.
If no exclusion exists, the patient will be randomized
immediately to HBO2T or standard of care treatment. HBO2T
will consist of 100% oxygen at 2.4 ATA for 90 min daily for one
week. Multiple dose therapy is selected because of the time
course of secondary injury associated with TBI.
Myringotomy or temporary grommets will be at the
discretion of the HBO2T physician.
Patients will have a repeat MRI at 72 h for comparison. All
patients enrolled will undergo mRS, Barthel index and
Glasgow outcomes scale assessment at 7 days. These
assessments will be repeated at 6 and 12 months. All
evaluations will be done by examiners blinded to treatment
status.Primary outcomes will be modiﬁed Rankin scale score and
mortality. Secondary outcomes will include Barthel index
score, Glasgow outcome scale score, MRI appearance and need
for ICP lowering therapy. Total doses of ICP lowering
therapeutic agents or number of episodes of increased ICP
will be tracked.
Secondary analyses should take into account the age of the
patient at the time of injury as treatment with HBO2T, an anti-
apoptotic regimen, may have some deleterious effects on very
young patients who are still undergoing planned apoptosis as
part of normal brain development [53]. For similar reasons,
there may also be some beneﬁt, particularly in patients under
age 25, to prolonged monitoring past one year for optimal
outcome measures.
Radiation induced cerebral necrosis
Speciﬁc aim
Determine whether HBO2T treatment of radiation necrosis of
brain results in improvement of neurological function and
reduction of necrosis.
Radiation induced cerebral necrosis (RICN) is a dreaded
complication associated with the treatment of various brain
pathologies (metastases, arteriovenous malformations) with
radiotherapy or radiosurgery. The neurologic signs and
symptoms that result are often progressive and can be difﬁcult
to distinguish from tumor recurrence [54]. The most common
presentations involve headache and other signs of elevated
intracranial pressure, but can also include cognitive changes
such as short term memory loss, poor concentration,
personality changes, and focal neurologic abnormalities such
as hemi-paresis and aphasia [55].
Radiation necrosis tends to be a delayed toxicity from
radiation and is often detected as a result of abnormal contrast
enhanced imaging within the radiated ﬁeld [56]. This is
presumed to be due to radiation damage to the vasculature
such that capillaries leak contrast dye. This effect also results
in increased edema in the brain that can lead to signs and
symptoms of elevated intracranial pressure. Although steroids
may also have a stabilizing effect on the necrotic tissue, they
tend not to reverse the radiation necrosis itself [57].
Various imaging studies have been performed to distin-
guish necrosis from tumor recurrence, as tumor recurrence
would need further treatment and necrosis may be treated
symptomatically with non-surgical interventions. MR spec-
troscopy, PET scanning, SPECT scanning and MR perfusion
studies have been largely unsuccessful with insufﬁcient
sensitivity such that the gold standard of diagnosis is still
surgical excision [58–60].
Treatment of radiation necrosis of the brain is difﬁcult.
Steroids tend to provide symptomatic relief and at the expense
of signiﬁcant side effects such as myopathy, hyperglycemia,
osteoporosis and psychological manifestations. Surgical
resection may stop progression, however, at the expense of
a major operation. Often patients with metastatic disease are
too sick to undergo such procedures and treated with
prolonged steroids as the alternative [61]. HBO2T has been
very successful in treating radiation injuries in other tissues in
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endothelial cell damage and microvascular ischemia are
considered to be part of the injury cascade in such soft tissue
radiation injuries, hyperbaric oxygen therapy may be a viable
treatment alternative for RIN as well [62].
There has been only one small, phases I–II randomized
controlled study investigating the use of HBO2T in RIN.Hulshof
et al. [63] randomized 7 patients with cognitive deﬁcits at least
1.5 years after brain irradiation to receive either 30 HBO2T
treatments at 3.0 ATA for 115 min, or no treatment. Using
a battery of neuropsychological tests as outcome measures,
they found a trend towards improved function at three
months in the treatment group, but this result was not
statistically signiﬁcant. There have also been numerous
anecdotal reports of efﬁcacy and a few short uncontrolled
series reporting positive results [64–67]. In the largest series,
reported only in abstract form, Warnick et al. [68] included 29
patients with RIN of the brain receiving HBO2T at 2.5 ATA over
90 min for 20–60 treatments. All of the patients in the study
had focal, progressive neurological deﬁcits with increasing
steroid requirements and an MRI showing a ring-enhancing
mass with surrounding edema consistent with necrosis. In
this series, 27 of the 29 patients showed improvement or
stabilization of symptoms, decreased steroid requirement,
and improved MRI appearance. The 2 patients who worsened
were shown to have tumor progression. Interestingly, the
greatest beneﬁt was noted in a subset of 4 patients with benign
underlying pathology (meningioma andAVM). Chuba et al. [69]
also reported beneﬁt in a group of 10 pediatric patients who
underwent HBO2T after a diagnosis of RIN and failure of
traditional steroid therapy. All ten patients showed clinical
improvement or stabilization both initially and at follow-up,
while 5 of the 6 surviving patients showed continued
improvement. The 4 deaths in this group were attributed to
tumor progression.
The evidence suggests that in cases where either the
patient is not improving on medical therapies, such as
steroids, or when surgical resection is not possible, HBO2T
could be considered as a treatment option. Due to the lack of
studies currently available in this ﬁeld, there is a deﬁnite need
for both more and larger randomized trials utilizing HBO2T for
the treatment of RIN.
Study design
Inclusion criteria would enroll male and female patients at
least 18years-oldwhohaveahistoryof radiation to thebrain for
either malignant or benign brain lesions resulting in necrosis.
The patient must have an MRI of the brain and evidence of
a lesion in the radiation ﬁeld that is consistentwithRIN andnot
tumor progression. In patients with a history of malignant
tumor, a negative biopsy is required to differentiate between
tumor recurrence and radiation induced necrosis. Patientswith
any evidence of recurrent tumor will be excluded.
A headMRI will be used for comparison and also to identify
other intracranial pathology that would warrant exclusion.
Patients with cancermust also have full staging investigations
to rule out other sites of disease progression and cannot
actively be receiving chemotherapy or radiotherapy.If no exclusion exists, the patient will be randomized to
HBO2T or standard of care treatment. HBO2T will consist of
100% oxygen at 2.4 ATA for 90 min daily, at least 5 days per
week, for 30 treatments. The selection of this regimen is based
both on the safety and efﬁcacy observed in other FDAapproved
uses including radiation necrosis of non-neural soft tissues.
All patients will be monitored throughout their treatment
period for progression of symptoms and their steroid
requirement. They will also receive repeat MRI scans of the
head after completion of the treatment protocol (30 days) and
again and at 90 days following completion of treatment
protocol. Formal neuropsychological evaluationwill be done at
enrollment and repeated at 90 days post-treatment. Quality of
life measures, such as the EORTC QLQ-C30 and BN 20 will be
administered at enrollment and 90 days as well [70, 71].
Primary outcomes will be progression, stabilization or
resolution of symptoms measured by the neurologist, as well
as progression, stabilization, or resolution of the lesions on
MRI imaging where RECIST (response evaluation criteria in
solid tumors) criteria will be applied [72]. Secondary outcomes
will include change in neuropsychological measures and, the
steroid requirement as compared to control. All measures will
be assessed at 90 days post-treatment.
Migraine
Speciﬁc aim
To determinewhether use of HBO2Twill relieve headache pain
in status migrainosus.
Migraine is a common disorder. One-year prevalence is
approximately 18% and 7% for American woman and men,
respectively [73]. Status Migrainosus, as deﬁned by The
International Headache Society's International Classiﬁcation
of Headache Disorders, 2nd edition [74], is a migraine attack
lastingmore than 72 h that is typical of previous attacks except
in duration, and that cannot be attributed to another disorder.
While usually felt to be a rare phenomenon, in a recent
retrospective study, 20% of migraineurs reported episodes
whichmet these criteria [75]. Current knowledge suggests that
primary neuronal dysfunction leads to intracranial and
extracranial changes that account for migraine [76]. Those
prone to migraine have a genetic migrainous threshold that
leaves them susceptible to acute attacks, dependent on the
balance of excitation and inhibition at various levels of the
nervous system. Genetic and environmental factors both play
a role [77]. Nevertheless, it is believed that vasodilatation still
plays an integral part in the severe throbbing pain characte-
ristic ofmigraine, likely secondary to instability in the central
neurovascular control mechanism [78]. It has been suggested
that prolonged dilation of blood vessels is associated with an
increased risk of stroke [74]. Additionally, it has been
theorized that release of nitric oxide by nerves, vessels, or
brain tissuemay be part of the trigger of formigraine pain [79].
Hyperbaric oxygen causes cerebral vasoconstriction, likely
though scavenging of nitric oxide [80] and thus the effect of
HBO2T might improve pain directly through decreases in NO
as well as through vasoconstriction and anti-inﬂammatory
mechanisms.
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treatment of acute migraine attack. Wilson et al. [81] assigned
female subjects with conﬁrmed migraine to either 100%
oxygen at normal pressures, or hyperbaric oxygen. They
found that subjective pain was signiﬁcantly reduced in the
group receiving hyperbaric oxygen, but not following control
treatment. They concluded that HBO2T is effective for
migraine pain, and the patient's subjective pain assessment
was the best indicator of relief. In a double blind, placebo-
controlled study by Eftedal et al. [82] the prophylactic effect of
HBO2T on migraine was investigated. Forty patients were
randomly assigned to a treatment group receiving three
sessions of hyperbaric oxygen, or a control group receiving
three hyperbaric air treatments. Patients kept a standardized
migraine diary for eight weeks before and following treat-
ments. Thirty-four patients completed the study. Their
primary measure of efﬁcacy was the difference between
pre- and post-treatment hours of headache per week. The
results showed a non- signiﬁcant reduction in hours of
headache between groups. Levels of endothelin-1 in venous
blood pre- and post-treatment showed no difference between
the hyperbaric oxygen and control groups. They concluded that
the tested protocol does not show a signiﬁcant prophylactic
effect on migraine and does not inﬂuence the level of
endothelin-1 in venous blood. Bennett et al. [83] conducted
a meta-analysis on randomized trials comparing HBO2T or
normobaric oxygen with placebo or no treatment in patients
with migraine headache or cluster headache. Nine small trials
were included which involved 201 participants. Five trials
compared HBO2T vs sham therapy for migraine. Pooling data
fromthree trials suggested thatHBO2Twaseffective in relieving
migraine headache compared to sham (relative risk (RR) 5.97,
95% conﬁdence interval (CI) 1.46–24.38, P = 0.01). However, no
evidence was found for prophylactic use. No reduction in the
incidence of nausea and vomiting was seen. Neither was there
a reduction in rescue medication requirements. We are not
aware of data looking at HBO2T as a therapy for status
migrainosus.
Study design
Patients arriving to the Emergency Department with
a presumed diagnosis of status migrainosus by history will
be evaluated by a neurologist. Inclusion in the study requires
that the patient, eithermale or female, be at least 18 years-old
and have prior history of migraine consistent with current
headache except in duration. Headache must have been
present for a minimum of 72 h, with no period of time being
pain free greater than 4 h. Past medical history will be
gathered to assess for possible contraindications. Other
causes of headachewill be ruled outwith appropriate imaging
and laboratory studies. Patients with headache possibly
attributed to other cause will be excluded. Patients without
prior migraine, with sudden onset pain (i.e. thunderclap
headache), with focal neurologic deﬁcits (other than visual
ﬁeld changes), or other evidence of underlying neurologic
pathology will be excluded. Head pain must be refractory to
current standard or care treatment for status migrainosus. If
pain responds to treatment, as deﬁned by a 50% reduction inpain on a 10 point visual analog pain scale, the patient will be
excluded.
A CT of the head at presentation will be obtained to assess
for intracranial pathology that would warrant exclusion.
Subjects should be screened to exclude signiﬁcant risks for
undergoing an extended course of HBO2T including ejection
fraction of <35%, an ABG, and radiographic evidence of
pulmonary blebs or bullae. Prior to treatment the patient will
report subjective level of pain based on the visual analog pain
scale, due to prior studies showing this measure was the best
indicator of relief.
If no exclusion exists, the patient will be randomized to
HBO2T or sham treatment. Only the technician administrating
the therapy will be aware of which treatment the patient
receives. HBO2T will consist of 100% oxygen at 2.4 ATA for
90 min for one treatment.
Post-treatment the patient will again be assessed for pain
based on visual analog pain scale. A positive response will be
deﬁned as a 50% pain reduction using a 10 point visual analog
pain scale which will serve as the primary outcome of the
study. Patients will also be assessed, directly or by phone, at
24 and 48 h for duration of the effect of the therapy and
frequency of recurrence of migraine pain.
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